FiercePharmaOriginal article
{"a":[{"_":"Sanofi unit in Ireland chided by FDA over manufacturing flubs linked to Altuviiio","$":{"href":"/pharma/sanofi-unit-ireland-chided-fda-over-manufacturing-flubs-linked-altuviiio","hreflang":"en"}}]}
RegulatoryAltuviiioNegative
AI Analysis
Summary
Sanofi's Genzyme Ireland subsidiary received an FDA Form 483 following an inspection in early 2026 related to manufacturing issues with Altuviiio, and faces further regulatory action from the U.S. regulator.
Outcome Details
FDA Form 483 issued following site visit inspection at Genzyme Ireland in early 2026; subsidiary facing further reprimand from FDA
Importance:6/10
Sentiment:
-0.70
FDA inspectionmanufacturingregulatory actionForm 483Genzyme Ireland
Related Companies
Read the original article
Published by FiercePharma on July 1, 2026 2:32 PM